人胰島素市場：按產品類型、按地區 - 規模、份額、展望、機會分析，2022-2028 年

Human Insulin Drug Market, By Product Type and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年11月03日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

胰島素是一種用於控制高血糖（血糖）水平的藥物製劑。用於控制 1 型和 2 型糖尿病患者的血糖水平。糖尿病患者需要胰島素作為治療的一部分。胰島素有助於將血液中的糖分轉移到其他身體組織，在那裡它可以用作能量。這樣，隨著糖尿病患者數量的增加，全世界對胰島素製劑的需求也在增加。

市場動態

糖尿病發病率的增加、對人胰島素製劑的需求增加、公眾對胰島素的認識提高、對新藥開發的關注度增加、生物仿製藥的採用增加、有利的政府政策等預計將成為推動胰島素增長的主要因素人胰島素市場。

2022年1月，諾和諾德宣佈在印度推出用於治療2型糖尿病的口服semaglutide。口服 semaglutide 是一種胰高血糖素樣□ (GLP-1) 受體類似物分子，有望成為糖尿病的治療藥物。此外，2021 年 8 月，美國食品和藥物管理局 (USFDA) 批准了禮來公司的速效胰島素 LumeJev（賴脯胰島素注射液）100 單位/mL，用於治療 1 型和 2 型糖尿病。獲批的擴展適應症包括通過胰島素泵持續皮下輸注以改善患者的血糖控制。

這項研究的主要特點

本報告對全球人胰島素市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2028 年）的市場規模和復合年增長率 (CAGR%)。。
它還揭示了不同細分市場的潛在創收機會，並為市場勾勒出一個有吸引力的投資建議矩陣。
它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
它根據以下參數（包括公司亮點、產品組合、主要亮點、績效和戰略）介紹了全球人胰島素市場的主要參與者。
本研究涵蓋的主要公司包括 Wockhardt、SEDICO、Exir、Julphar、Biocon、Eli Lilly、Sanofi Aventis 和 Novo Nordisk AS 等。
這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
本報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以通過用於分析全球人胰島素市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

報告內容
- 市場定義和範圍
執行摘要
- 按產品類型劃分的市場概況
- 市場概況：按地區
連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

市場動態
- 全球糖尿病患病率上升
- 胰島素價格飆升
- 越來越關注新藥開發
影響分析
主要亮點
監管場景
產品發布/批准
害蟲分析
對 PORTER 的分析
合併/收購場景

第 4 章全球人用胰島素產品市場 - COVID-19 大流行的影響

COVID-19 的流行病學特徵
供應方和需求方分析
經濟影響

第 5 章全球人胰島素市場：按產品類型，2017-2028

人胰島素
基礎胰島素
推注胰島素
胰島素組合藥物
胰島素生物仿製藥

第 6 章全球人胰島素市場：地區，2017-2028

北美
歐洲
亞太地區
世界其他地方

第七章競爭格局

Wockhardt
SEDICO
Exir
Julphar
Biocon
Eli Lilly
Sanofi Aventis
Novo Nordisk AS

第 8 章

調查方法介紹
關於出版商

簡介目錄

Product Code: CMI5316

Insulin is a pharmaceutical preparation used to control high blood glucose (blood sugar level). It is used to control blood sugar in people with type 1 and type 2 diabetes. People with diabetes require insulin as part of their treatment. It works by helping move sugar from the blood into other body tissues where it is used for energy. Thus, with the increase in prevalence of diabetes, the demand for insulin drugs is also increasing worldwide.

Market Dynamics:

Increasing incidence of diabetes, increase in demand for human insulin drugs, rise in awareness among people about insulin, increase in focus on the development of novel drugs, increase in adoption of biosimilars, and favorable government policies are major factors expected to drive growth of the global human insulin drug market.

In January 2022, Novo Nordisk announced the launch of oral semaglutide in India to treat type 2 diabetes. Oral semaglutide, a glucagon-like peptide (GLP-1) receptor analogue molecule, is a promising addition to diabetes treatment. Moreover, in August 2021, the U.S. Food and Drug Administration (USFDA) approved an expanded label for Eli Lilly and Company's rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in individuals with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion with an insulin pump.

Key features of the study:

This report provides in-depth analysis of the global human insulin drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global human insulin drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Wockhardt, SEDICO, Exir, Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global human insulin drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market.

Detailed Segmentation:

Global Human Insulin Drug Market, By Product Type:
- Human Insulin
- Basal Insulin
- Bolus Insulin
- Insulin Combinations
- Biosimilar Insulins
Global Human Insulin Drug Market, By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Company Profiles:
- Wockhardt
- SEDICO
- Exir
- Julphar
- Biocon
- Eli Lilly
- Sanofi Aventis
- Novo Nordisk AS

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Basal Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Bolus Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Insulin Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Biosimilar Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Human Insulin Drug Market, By Geography, 2017-2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

7. Competitive Landscape

Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
SEDICO
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Exir
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi Aventis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views